Grupo Español de Estudio de la Nefropatía Diabética - Artículos en Revistas
| ARTÍCULOS EN REVISTAS |
| AÑO 2021 |
|
Martinez-Castelao A, Górriz Teruel JL, Garrigós E, Fernández Fresnedo G, Espinel Garuz E, Cigarrán Guldris S, Robles Pérez-Monteoliva NR, Arteaga Colona J, D Marco L, Navarro González JF and investigatrs of the PROGRESER study. Factors fpr progression of CKD-3 in diabetic and non-diabetic patients. PROGRESER study. (submitted). |
|
Sánchez-Alamo B, García-Iñigo FJ, Shabaka A, Acedo JM, Cases-Corona C, Domínguez-Torres P, Diaz-Enamorado Y, Landaluce E, Navarro-González JF, Gorriz JL, Martínez-Castelao A, Fernández-Juárez G. Urinary Dickkopf-3 (uDKK3): a new biomarker for CKD progression and mortality? Nephrol Dial Transplant. 2021 Jun 17:gfab198. doi: 10.1093/ndt/gfab198. Online ahead of print.PMID: 34145894. |
|
Martínez-Castelao A, Soler MJ, Górriz Teruel JL, Navarro-González JF, Fernandez-Fernandez B, de Alvaro Moreno F, Ortiz A. Optimizing the timing of nephrology referral for patients with diabetic kidney disease. Clin Kidney J. 2020 Aug 5;14(1):5-8. doi: 10.1093/ckj/sfaa125. eCollection 2021 Jan. |
|
Navarro-González JF; Arenas MD; Henríquez-Palop F; Lloret MJ; Molina P; Ríos Moreno F; Macia-Lagier MA; Espinel L; Sánchez E; Lago M; Crespo A; Bover J. Real-world management of hyperphosphataemia with sucroferric oxyhydroxide: the VELREAL multicentre study. Clinical Kidney Journal. 14 - 2, pp. 681 - 687. Oxford University Press, 2021. |
|
Donate-Correa J; Martín-Núñez E; González-Luis A; Ferri CM; Luis-Rodríguez D; Tagua VG; Mora-Fernández C; Navarro-González JF. Pathophysiological implications of imbalances in fibroblast growth factor 23 in the development of diabetes. Journal of Clinical Medicine. 10, pp. 2583. MDPI, 2021. |
|
Arenas Jiménez MD; González-Parra E; Riera M; Rincón Bello A; López-Herradón A; Cao H; Hurtado S; Collado S; Ribera L; Barbosa F; Dapena F; Torregrosa V; Broseta JJ; Soto Montañez C; Navarro-González JF; Ramos R; Bover J; Nogués-Solán X; Crespo M; Dusso AS; Pascual J. Mortality in hemodialysis patients with COVID-19, the effect of paricalcitol or calcimimetics. Nutrients. 13, pp. 2559. MDPI, 2021. |
|
Rodriguez Diez RR; Tejera Muñoz A; Orejudo M; Marquez Expósito L; Santos L; Rayego Mateos S; Cantero Navarro E; Tejedor Santamaría L; Marchant V; Ortiz A; Egido J; Mezzano S; Selgas R; Navarro González JF; Valdivielso JM; Lavoz C; Ruiz Ortega M. Interleukin 17-A: Possible mediator and therapeutic target in hypertension. NEFROLOGIA. 41 - 3, pp. 244 - 257. 2021. |
|
Donate Correa J; Ferri CM; Sánchez Quintana F; Pérez Castro A; González Luis A; Martín Núñez E; Mora Fernández C; Navarro González JF. Inflammatory cytokines in diabetic kidney disease: pathophysiologic and therapeutic implications. Frontiers in Medicine. 7, pp. 628289. 2021. |
|
Pérez-Morales R; Donate-Correa J; Martín-Núñez E; Pérez-Delgado N; Ferri C; López-Montes A; Jiménez-Sosa A; Navarro-González JF. Extracellular water/total body water ratio as predictor of mortality in hemodialysis patients. Renal Failure. 43, pp. 821 - 829. Taylor & Francis, 2021. |
|
Díez J; Navarro-González JF; Ortiz A; Santamaría R; De Sequera P. Developing the subspeciality of cardio-nephrology: the time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. NEFROLOGIA. 41, pp. 391 - 402. 2021. |
|
Sierra Ramos C; Velazquez García S; Keskus AG; Vastola Mascolo A; Rodríguez Rodríguez AE; Luis Lima S; Hernández G; Navarro González JF; Porrini E; Konu O; Alvarez de la Rosa D. Increased SGK1 activity potentiates mineralocorticoid/NaCL-induced kidney injury. American Journal of Physiology Renal Physiology. 320, pp. F628 - F643. 2021. |
|
Luis Rodríguez D; Donate Correa J; Martín Núñez E; Ferri C; G. Tagua V; Pérez Castro A; Mora Fernández C; Navarro González JF. Serum urate is related to subclinical inflammation in asymptomatic hyperuricemia. Rheumatology. 60, pp. 371 - 379. 2021. |
|
Donate-Correa J; Ferri CM; Martín-Núñez E; Pérez-Delgado N; González-Luis A; Mora-Fernández C; Navarro-González JF. Klotho as a biomarker of subclinical atherosclerosis in patients with moderate to severe chronic kidney disease. Scientific Reports. 11, pp. 15877. Springer Nature, 2021. |
|
Bermejo S, García-Carro C, Soler MJ. Diabetes and renal disease-should we biopsy? Nephrol Dial Transplant. 2021 Jul 23;36(8):1384-1386. doi: 10.1093/ndt/gfz248.PMID: 31883322 No abstract available. |
| AÑO 2020 |
|
Soler MJ, Porrini E, Fernandez-Fernandez B, Ortiz A. SGLT2i and postglomerular vasodilation. Kidney Int. 2020 Apr;97(4):805-806. doi: 10.1016/j.kint.2020.01.007.PMID: 32200864 |
|
Bermejo S, González E, López-Revuelta K, Ibernon M, López D, Martín-Gómez A, Garcia-Osuna R, Linares T, Díaz M, Martín N, Barros X, Marco H, Navarro MI, Esparza N, Elias S, Coloma A, Robles NR, Agraz I, Poch E, Rodas L, Lozano V, Fernández B, Hernández E, Martínez MI, Stanescu RI, Moirón JP, García N, Goicoechea M, Calero F, Bonet J, Galceran JM, Liaño F, Pascual J, Praga M, Fulladosa X, Soler MJ. Risk factors for non-diabetic renal disease in diabetic patients. Clin Kidney J. 2020 Jan 3;13(3):380-388. doi: 10.1093/ckj/sfz177. eCollection 2020 Jun.PMID: 32699618 |
|
Górriz JL; Navarro-González JF; Ortiz A; Vergara A; Núñez J; Jacobs-Cachá C; Martínez-Castelao A; Soler MJ. Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease. Nephrology Dialysis & Transplantation. 35 - Supl. 1, pp. 13 - 23. Oxford Academic, 2020. |
|
Fernández Fernández B; Sarafidis P; Kanbay M; Navarro-González JF; Soler MJ; Górriz JL; Ortiz A. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. Clinical Kidney Journal. 13, pp. 728 - 733. Oxford University Press, 2020. |
|
Castro Alonso C; D'Marco L; Pomes J; Del Amo Conill M; García Díez AI; Molina P; Puchades MJ; Valdivielso JM; Escudero V; Bover J; Navarro-González JF; Ribas B; Pallardó LM; Górriz JL. Prevalence of Vertebral Fractures and Their Prognostic Significance in the Survival in Patients with Chronic Kidney Disease Stages 3‒5 Not on Dialysis. Journal of Clinical Medicine. 9, pp. 1604. MDPI, 2020. |
|
Arenas Jiménez MD; Navarro-González JF. How to improve adherence the captors of phosphorus on hemodialysis: Experience in real life with sucroferric oxyhydroxide. NEFROLOGÍA. 40, pp. 640 - 646. Elsevier, 2020. |
|
Lavoz C; Rayego-Mateos S; Orejudo M; Opazo-Ríos L; Marchant V; Márquez-Expósito L; Tejera-Muñoz A; Navarro-González JF; Droguett A; Ortiz A; Egido J; Mezzano S; Rodrigues-Diez RR; Ruiz-Ortega M. Could IL-17 be a novel therapeutic target in diabetic nephropathy?. Journal of Clinical Medicine. 9, pp. 272. MDPI, 2020. |
|
Donate-Correa J; Luis-Rodríguez D; Martín-Núñez E; G Tagua V; Hernández-Carballo C; Ferri C; Rodríguez-Rodríguez AE; Mora-Fernández C; Navarro-Gonzñalez JF. Inflammatory targets in diabetic nephropathy. Journal of Clinical Medicine. 9 - 2, pp. 458. MDPI, 2020. |
|
Martín-Núñez E; Donate-Correa J; Ferri C; López-Castillo A; Delgado-Molinos A; Hernández-Carballo C; Pérez-Delgado N; Rodríguez-Ramos S; Cerro-López P; G Tagua V; Mora-Fernández C; Navarro-González JF. Association Between Serum Levels of Klotho and Inflammatory Cytokines in Cardiovascular Disease: A Case-Control Study. Aging (Albany NY). 12 - 2, pp. 1952 - 1964. Impact Journals LLC, 2020. |
| Górriz JL, Soler MJ, Navarro-González JF, García-Carro C, Puchades MJ, D'Marco L, Martínez Castelao A, Fernández-Fernández B, Ortiz A, Górriz-Zambrano C, Navarro-Pérez J, Gorgojo-Martinez JJ. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists J Clin Med. 2020 Mar 30;9(4):947. doi: 10.3390/jcm9040947 |
| AÑO 2019 |
|
Martín-Núñez E; Donate-Correa J; Kannengiesser C; De Brauwere DP; Leroy C; Oudin C; Friedlander G; Prieto-Morín C; G. Tagua V; Ureña-Torres P; Navarro-González JF. A novel heterozygous deletion variant in KLOTHO gene leading to haploinsufficiency and impairment of fibroblast growth factor 23 signaling pathway. Journal of Clinical Medicine. 8, pp. E500. MDPI, 2019. |
|
Valdivielso JM; Bozik M; Galimudi RK; Bermúdez-López M; Navarro-González JF; Fernández E; Betriu A. Association of the rs495392 Klotho polymorphism with atheromatosis progression in chronic kidney disease patients. Nephrology Dialysis & Transplantation. 34, pp. 2079 - 2088. Oxford University Press, 2019. |
|
Fernández Fernández B; Fernández Prado R; Górriz JL; Martínez Castelao A; Navarro González JF; Porrini E; Soler MJ; Ortiz A. Canagliflozin and renal events in diabetes with established nephropathy clinical evaluation and Study of diabetic nephropathy with atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?. Clinical Kidney Journal. 12, pp. 313 - 321. 2019. |
|
Donate-Correa J; Ferri C; Martín-Núñez E; Hernández-Carballo C; Tagua VG; Delgado-Molinos A; López-Castillo A; Rodríguez-Ramos S; Cerro-López P; López-Tarruella VC; Arévalo-González MA; Pérez-Delgado N; Mora-Fernández C; Navarro-González JF. FGF23 and Klotho levels are independently associated with diabetic foot syndrome in type 2 diabetes mellitus. Journal of Clinical Medicine. 2019 - 8, pp. E448. MDPI, 2019. |
|
Donate Correa J; Martín Núñez E; Hernández Carballo C; Ferri C; Tagua VG; Delgado Molinos A; López Castillo A; Rodríguez Ramos S; Cerro López P; López Tarruella V; Felipe García R; Arévalo-Gómez MA; Pérez Delgado N; Mora Fernández C; Navarro González JF. Fibroblast growth factor 23 expression in human calcified vascular tissues. Aging-US. 11, pp. 7899 - 7913. 2019. |
|
Pérez-Morales R; Del Pino MD; Valdivielso JM; Ortiz A; Mora-Fernández C; Navarro-González JF. Inflammation in diabetic kidney disease. Nephron. 143, pp. 12 - 16. KARGER, 2019. |
|
Donate-Correa J; G. Tagua V; Ferri C; Martín-Núñez E; Hernández-Carballo C; Ureña-Torres P; Ruiz-Ortega M; Ortiz A; Mora-Fernández C; Navarro-González JF. Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons. Journal of Clinical Medicine. 8, pp. 287. MDPI, 2019. |
| AÑO 2018 |
|
Górriz JL, Martínez-Castelao A, Navarro-González JF y Tejedor Jorge A: Diabetes mellitus tipo 2, enfermedad cardiovascular y enfermedad renal crónica. Sociedad Española de Cardiologia. Monografías, 2018; 6(2):24-34. En: Sociedad Española Cardiologia, Monografias:Diabetes tipo 2 , Recomendaciones de tratamiento. Almudena Castro-Conde, Domingo Marzal-Martín.2018;6(2):1-56. |
|
Navarro-González JF, Sánchez-Niño MD, Donate-Correa J, Martín-Núñez E, Ferri C, Pérez-Delgado N, Górriz JL, Martínez-Castelao A, Ortiz A, Mora-Fernández C Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease. ERBP guideline on management of patients with diabetes and chronic kidney disease stage 3B or higher. Metformin for all?. Diabetes Care. 2018 Aug;41(8):1817-1820. doi: 10.2337/dc18-0078. Epub 2018 Jun 4. |
|
Martínez Martínez-Castelao 1,A, Soler ;J2, Navarro-González JF3, Górriz JL4í Will the new molecules be effective in renal and cardiovascular protection in diabetes mellitus and diabetic kidney disease?. Nefrologia (Engl Ed) Jan-Feb 2019;39(1):3-10. doi: 10.1016/j.nefro.2018.05.011. Epub 2018 Oct DOI: 10.1016/j.nefro.2018.05.011 |
|
AÑO 2017 |
|
Martínez-Castelao A, Górriz JL, Ortiz A, Navarro-González JF ERBP guideline on management of patients with diabetes and chronic kidney disease stage 3B or higher. Metformin for all?. Nefrologia. 2017 Nov-Dec;37(6):567-571. doi: 10.1016/j.nefro.2017.06.001. Epub 2017 Jun 29. |
|
AÑO 2015 |
|
Martínez-Castelao A, Navarro-González JF, Górriz JL, de Alvaro F. The Concept and the Epidemiology of Diabetic Nephropathy Have Changed in Recent Years.J Clin Med. 2015 May 28;4(6):1207-16. doi: 10.3390/jcm4061207. |
|
Górriz JL, Nieto J, Navarro-González JF, Molina P, Martínez-Castelao A, Pallardó LM. Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? J Clin Med. 2015 Oct 23;4(10):1866-89. doi: 10.3390/jcm4101866.PMID: 26512703 Free PMC article. Review. |
| AÑO 2014 |
|
Martínez-Castelao A, Górriz JL, Segura-de la Morena J, Cebollada J, Escalada J, Esmatjes E, Fácila L, Gamarra J, Gràcia S, Hernánd-Moreno J, Llisterri-Caro JL, Mazón P, Montañés R, Morales-Olivas F, Muñoz-Torres M, de Pablos-Velasco P, de Santiago A, Sánchez-Celaya M, Suárez C, Tranche S. Consensus document for the detection and management of chronic kidney disease. Nefrologia. 2014;34(2):243-62. doi: 10.3265/Nefrologia.pre2014.Feb.12455.PMID: 24658201 Free article. English, Spanish. |
|
Martínez-Castelao A, Górriz JL, Bover J, Segura-de la Morena J, Cebollada J, Escalada J, Esmatjes E, Fácila L, Gamarra J, Gràcia S, Hernández-Moreno J, Llisterri-Caro JL, Mazón P, Montañés R, Morales-Olivas F, Muñoz-Torres M, de Pablos-Velasco P, de Santiago A, Sánchez-Celaya M, Suárez C, Tranche S. [Consensus document for the detection and management of chronic kidney disease]. Aten Primaria. 2014 Nov;46(9):501-19. doi: 10.1016/j.aprim.2014.09.002. Epub 2014 Oct 5.PMID: 25288498 Free PMC article. Spanish. |
|
Martínez-Castelao A, Górriz JL, Bover J, Segura-de la Morena J, Cebollada J, Escalada J, Esmatjes E, Fácila L, Gamarra J, Gràcia S, Hernández-Moreno J, Llisterri-Caro JL, Mazón P, Montañés R, Morales-Olivas F, Muñoz-Torres M, de Pablos-Velasco P, de Santiago A, Sánchez-Celaya M, Suárez C, Tranche S. [Consensus document for the detection and management of chronic kidney disease]. Endocrinol Nutr. 2014 Nov;61(9):e25-43. doi: 10.1016/j.endonu.2014.06.003. Epub 2014 Aug 27.PMID: 25171835 Spanish. |
| Gómez-Huelgas R, Martínez-Castelao A, Artola S, Górriz JL, Menéndez E; en nombre del Grupo de Trabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica. Treatment of type 2 diabetes mellitus in patients with chronic kidney disease. Med Clin (Barc). 2014 Jan 21;142(2):85.e1-10. doi: 10.1016/j.medcli.2013.10.011. Epub 2013 Nov 21. Spanish |
| Gómez-Huelgas R, Martínez-Castelao A, Artola S, Górriz JL, Menéndez E; Grupo de Tabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica. Consensus document on treatment of type 2 diabetes in patients with chronic kidney disease. Nefrologia. 2014;34(1):34-45. Spanish. |
| Mora-Fernández C, Domínguez-Pimentel V, de Fuentes MM, Górriz JL, Martínez-Castelao A, Navarro-González JF. Diabetic kidney disease: from Physiology to Therapeutics. J Physiol. 2014 Jun 6. [Epub ahead of print] Review. PMID:24907306 |
| AÑO 2013 |
| Fernández-Juárez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Lahera V, Casas L, Oliva J; PRONEDI Study Group. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system. Clin J Am Soc Nephrol. 2013 Nov;8(11):1870-6. doi: 10.2215/CJN.00910113. Epub 2013 Oct 17. |
| Portolés J, Gorriz JL, Rubio E, de Alvaro F, García F, Alvarez-Chivas V, Aranda P, Martinez-Castelao A; NADIR-3 Study Group. The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC Nephrol. 2013 Jan 7;14:2. doi: 10.1186/1471-2369-14-2. |
| de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM; BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013 Dec 26;369(26):2492-503. doi: 10.1056/NEJMoa1306033. Epub 2013 Nov 9. |
| Bonet J, Martínez-Castelao A, Bayés B: Metabolic syndrome in haemodialysis patients as a risk factor for new-onset diabetes mellitus after renal t5ransplant: a prospective observational study. Diabetes , Metabolic Syndrome & obesity: Targets & therapy 2013(6); 39-346. |
| AÑO 2012 |
| Comas J, Arcos E, Castell C, Cases A, Martínez-Castelao A, Doñate T, Esmatjes E. Evolution of the incidence of chronic kidney disease Stage 5 requiring renal replacement therapy in the diabetic population of Catalonia. Nephrol Dial Transplant. 2012 Nov 11. [Epub ahead of print] PMID:23147160 |
| Martínez-Castelao A, Górriz JL, Sola E, Morillas C, Jover A, Coronel F, Navarro-González J, de Álvaro F. Author Reply: About the discrepancies between consensus documents, clinical practice guidelines, and legal regulations in the treatment of type 2 diabetes. Nefrologia. 2012 Nov 21;32(6):835-837. doi: 10.3265/Nefrologia.pre2012.Oct.11731. PMID: 23169368 |
| Parving HH, Brenner BM, McMuray JJ, de Zeeuw D, Haffner SM, Solomon SD t al ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl JMed 2012; dec 6 637(23):2204-13 doi 10-1056/NEJMoa1208799, epun 3 nov. |
| Martínez-Castelao A, Solà E, Morillas C, Jover A,Górriz JL, Coronel F: Insuficiencia Renal en el paciente con diabetes mellitus tipo 2. Endocrinol Nutr.2012; 59(supl 3):20-29 |
| Discrepancies between the summary of characteristics and the recommended use of metformin in the treatment of type 2 diabetes mellitus patients. Górriz JL, Martínez-Castelao A, Sola E, Morillas C, Jover A, Coronel F, Navarro-González J, De Álvaro F. Nefrologia. 2012 Nov 21;32(6):838-839. doi: 10.3265/Nefrologia.pre2012.Oct.11783. PMID:23169371 |
| Martínez-Castelao A, Górriz JL, Solá E, Morillas C, Jover A, Coronel F, Navarro JF, de Alvaro F. A propósito de las discrepancias entre documentos de consenso, guías de práctica clínica y normative legal en el tratamiento de la diabetes tipo 2. Nefrología 2012; 32(4): 419-26 |
| AÑO 2011 |
| Serra N1, Oliveras A, Bergoñon S, Sans L , Cobos A, Martínez P, Artigas R, Poch E. Factors associated with blood pressure control in diabetic patients treated in nephrology units. PRESDIAB Study. Nefrologia. 2011;31(3):313-21. doi: 10.3265/Nefrologia.pre2011.Apr.10556 |
| Martinez Castelao A, Górriz JL, Portolés JM, de Alvaro F, Cases A, Luño J, Navarro JF, Montes R, de la Cruz-Troca JJ, Natarajan A, Batlle D. Baseline Characteristics of Patients with Chronic Kidney Disease Stage 3 and Stage 4 in Spain: the MERENA Observational Cohort Study. BMC Nephrology. 2011; Oct 5, 12:53 |
| De la Sierra A, Alegría E, Martínez Castelao A, Morillas C, González-Saegura D. Characteristics of patents with hypertension and metabolic syndrome atended by different specialists. Med Clin (Barcelona) 2011; Apr 19 Epub ahead of print |
| AÑO 2009 |
| Portolés JM, Martínez Castelao A, Górriz JL, Tato A, de Alvaro F. Anemia development and cardiovascular risk Management in nonanaemic stage 3 chronic kidney disease patients. Renal Failure 2009;31(10):869-75.PMID: 22421952 |
| Martínez Castelao A. Formación Continuada en Nefrología. El caso de la diabetes mellitus y la Enfermedad renal crónica. Nefrología 2009; (supl 5): 1-5. |
| AÑO 2006 |
| Alcázar R, González Albarrán O, Honorato J, Robles NR, Acha J, de Alvaro F, Fdez gallego V, Gómez García P, López de la Torre M, Nmartínez Casetlao A, Romero González R. Practical management of oral antidiabetic s in patients with renal disease . Nefrología 2006; 26(5): 538-558. |
| AÑO 2005 |
| Martínez-Castelao A, Hernández D, Pascual J et al. Detection and treatment of post Kidney Transplant hyperglycemia: a Spanish multicenter cross-sectional study. Transplant Proc 2005; 37 (9): 3813-3816. |
| De Alvaro, Martínez-Castelao A, Górriz JL. Importance of early determination of microalbuminuria in global vascular risk and diabetic nephropathy. Nefrología 2005; 25, supl 4: 35-41. |
| Martínez-Castelao A, de Alvaro F, Górriz JL, González MT. Nefrología Consensus guidelines for managing diabetic nephropathy: are they really valid?. Nefrología 2005; 25 supl 4:28-33. |
| Martínez-Castelao A, de Alvaro F, Górriz JL. Epidemiology of diabetic nephropathy in Spain. Kidney Int 2005; 68 (suppl 99): s20-s25. |
| AÑO 2004 |
| Martínez Castelao, A; Górriz JL, García-López F, López-Revuelta K, Cruzado JM: Perceived health-related quality of life and comorbidity in diabetic patients starting dialysis (CALVIDIA study). J. Nephrol 2004; 17:544-551. |
| Martínez Castelao A: Dislipemia y riesgo cardiovascular en pacientes diabéticos tipo 2 con nefropatía. Nefrología 2004; 24 (1): 51-52. |
| AÑO 2002 |
| Gerth W, Remuzzi G, Viberti G, Hannedouche T, Martínez-Castelao A, Shainfar S, Carides GW, Brenner B: Losartan reduces the burden and cost of ESRD: public halth implications from the RENAAL study for the European Union. Kidney Int 2002; 62 (suppl 82): S-68-S-72. |
| Documento de Consenso 2002 sobre detección, prevención y tratamiento de la nefropatía diabética en España. AENP, SED, SEEN, SEH-LELHA, SEMFYC, SEMERGEN, SEN. Comité de Redacción: F de Alvaro, A Martínez Castelao, R Romero. Nefrología 22(6): 521-530, 2002. |
| Martínez Castelao A, Ramos R, González MT, Castiñeiras MJ. Dislipemia y riesgo cardiovascular en el paciente diabético tipo 2 con nefropatía diabética asociada. Nefrología 2002; 22 (supl 1): 51-58. |
| AÑO 2001 |
| A Martínez Castelao, F de Alvaro,. J L Górriz. Tratamiento del paciente diabético con insuficiencia renal. Nefrología, 2001; 21(supl 3):66-75 |
| Brenner BM, Cooper M, de Zeeuw D et al (for the RENAAL Study Investigators). Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861-869. |
| AÑO 2000 |
| The Losartan renal Protection study. Rational study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). Brenner BM, Cooper ME, de Zeeuw D et al (for the RENAAL Study Investigators). JRAAS 2000; 1(4): 328-335. |
| AÑO 1999 |
| Insuficiencia renal secundaria a nefropatía diabética. revisión de las características de los pacientes diabéticos que iniciaron diálisis en Cataluña en 1994. MT González, C Castell, E Esmatges, R Tresserras, N de Lara, G Lloveras. Rev Clín. Esp. 1999; 199(1): 16-20, (A Martínez Castelao, lista investigadores). |
| AÑO 1997 |
| Renogram deconvolution in the management of diabetic nephropathy: utility of the measurement of initial tracer uptake. A Muñoz, R Puchal, AM Castelao, J Mora, Y Ricart, M Roca, A González, J Martín-Comín. Nuclear Med Communic. 18: 1029-1035, 1997. |
| Documento de consenso sobre pautas de detección y tratamiento de la nefropatía diabética en España. SE Nefrología. SE Diabetes. SE Endocrinología y Neutrición. SEMFYC. A Martínez-Castelao, coordinador de redacción. Nefrología, 17 (6): 467-474, 1997. |